Exodx prostate testing
Ended Awarded Last action
- Contract number
- 36C24622F0203
- Awardee
-
Exosome Diagnostics Inc. UEI TCKUCULVVY39
- Awarding agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $54,861
Award facts
- Contract value 8% obligated
-
- $130,012.16 Current, with exercised options
- $692,149.52 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Richmond, VA 23249, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$36,073 | |
| Supplemental Agreement for work within scope | -$37,576 | |
| Funding Only Action | $52,606 | |
| Exercise an Option | $0 | |
| Funding Only Action | -$52,606 | |
| Funding Only Action | -$21,794 | |
| Funding Only Action | $105,213 | |
| Exercise an Option | $0 | |
| Funding Only Action | -$69,140 | |
| Supplemental Agreement for work within scope | -$66,134 | |
| Funding Only Action | $105,213 | |
| Exercise an Option | $0 | |
| Original award | $75,152 |
Show all 13
About this award
Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, was awarded a $692,149.52 firm fixed-price delivery order by Veterans Integrated Service Network 6 (VISN 6) on May 13, 2022, for the provision of ExoDx Prostate (IntelliScore) testing services. The contract, which is a child award under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), requires performance through September 30, 2026, at the Richmond, VA location. This non-invasive, urine-based liquid biopsy test analyzes exosomal RNA biomarkers to assess the risk of clinically significant prostate cancer in veterans, representing an advanced alternative to traditional prostate cancer screening methodologies. No set-aside designation was used for this procurement.
The award reflects Exosome Diagnostics' sole-source status based on its unique diagnostic capabilities in extracellular vesicle analysis and exosomal RNA biomarker assessment. This delivery order is one of multiple contract awards the company has received from the Department of Veterans Affairs across several VISNs, demonstrating the VA healthcare system's continued reliance on this specialized liquid biopsy technology to support prostate cancer screening initiatives for eligible veterans. The firm fixed-price structure ensures cost certainty for the government while enabling consistent access to this innovative diagnostic tool across the VA system.
Quick answers
Who was awarded contract 36C24622F0203?
36C24622F0203 was awarded to Exosome Diagnostics Inc. by Veterans Integrated Service Network 6 (Veterans Health Administration) on May 13, 2022.
How much is contract 36C24622F0203 worth?
The government has obligated $54,861 on 36C24622F0203. Its current value, with exercised options, is $130,012. Its potential value, with all options, is $692,150.
Is contract 36C24622F0203 an order under another contract?
Yes. 36C24622F0203 is a delivery order under 36F79720D0097, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract 36C24622F0203 competed?
The extent of competition for 36C24622F0203 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award